References
- Look A T. Oncogenic transcription factors in the human acute leukemias. Science 1997; 278: 1059–1064
- Degos L, Wang Z Y. All trans-retinoic acid in acute promylocytic leukemia. Oncogene 2001; 20: 7140–7145
- Lehamnn S, Bengtzen S, Broberg U, Paul C. Effects of retinoids on cell toxicity and apoptosis in leukemic blast cells from patients with non-M3 AML. Leuk Res 2000; 24: 19–24
- Lutterbach B, Westendorf J J, Linggi B, Patten A, Moniwa M, Davie J R, et al. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 co-repressors. Mol Cell Biol 1998; 18: 7176–7184
- Lin R J, Evans R M. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Mol Cell 2000; 5: 821–830
- Nucifora G, Rowley J D. AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. Blood 1995; 86: 1–14
- Melnick A, Licht J D. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999; 93: 3167–3215
- Ferrara F F, Fazi F, Bianchini A, Padula F, Gelmetti V, Minucci S, et al. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res 2001; 61: 2–7
- Minucci S, Nervi C, Lo-Coco F, Pelicci P G. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias?. Oncogene 2001; 20: 3110–3115
- Zheng X, Seshire A, Rüster B, Bug G, Beissert T, Puccetti E, et al. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML-RARalpha-positive leukemic stem cells. Haematologica 2007; 92: 323–331
- Tallman M S, Andersen J W, Schiffer C A, Appelbaum F R, Feusner J H, Ogden A, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997; 337: 1021–1028
- Schlenk R F, Fröhling S, Hartmann F, Fischer J T, Glasmacher A, del Valle F, et al. Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia, Leukemia 2004; 18: 1798–1803
- Heuser M, Argiropoulos B, Kuchenbauer F, Yung E, Piper J, Fung S, et al. MN1 over-expression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML. Blood 2007; 110: 1639–1647
- van Wely K H, Meester-Smoor M A, Janssen M J, Aarnoudse A J, Grosveld G C, Zwarthoff E C. The MN1-TEL myeloid leukemia-associated fusion protein has a dominant-negative effect on RAR-RXR-mediated transcription. Oncogene 2007; 26: 5733–5740
- Sanz M A, Tallman M S, Lo-Coco F. Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia. Blood 2005; 105: 3019–3025